StockData
ELI LILLY & Co logo

ELI LILLY & Co

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)

Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%

Eli Lilly Immunology — Outside U.S. revenue by Year

Immunology — Outside U.S. revenue ($M) ($M)

QuarterlyAnnual

Eli Lilly Immunology — Outside U.S. revenue: $2,283M in FY2025, up 18.0% from a year earlier. That is the highest of the 10 years on record here.

Latest, FY2025
2,283
Period ended Dec 31, 2025
Change on a year earlier
+18.0%
1,935 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-12) ↗

Reported in Form 10-Q / 10-K Note 2.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedImmunology — Outside U.S. revenue ($M) ($M)Year on yearSource
FY2025Dec 31, 20252,283+18.0%Form 10-K (filed 2026-02-12) ↗
FY2024Dec 31, 20241,935+11.2%Form 10-K (filed 2026-02-12) ↗
FY2023Dec 31, 20231,740+19.9%Form 10-K (filed 2026-02-12) ↗
FY2022Dec 31, 20221,452-1.8%Form 10-K (filed 2025-02-19) ↗
FY2021Dec 31, 20211,479+35.7%Form 10-K (filed 2024-02-21) ↗
FY2020Dec 31, 20201,090+48.4%Form 10-K (filed 2023-02-22) ↗
FY2019Dec 31, 2019734+86.1%Form 10-K (filed 2022-02-23) ↗
FY2018Dec 31, 2018395+231.6%Form 10-K (filed 2021-02-17) ↗
FY2017Dec 31, 2017119+5,073.9%Form 10-K (filed 2020-02-19) ↗
FY2016Dec 31, 20162.30–Form 10-K (filed 2019-02-19) ↗

Cite this data

StockData. (2026). Eli Lilly Immunology — Outside U.S. revenue ($M), annual FY2016–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/ta-immunology-nonus

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.